Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era - PubMed
2 days ago
- #Metabolic liver disease
- #MASLD/HCC treatment
- #Drug repurposing
- Metabolic disorders elevate HCC risk through proinflammatory and molecular mechanisms in a dysmetabolic environment.
- Resmetirom is a selective THR-β agonist approved for MASH that enhances mitochondrial β-oxidation and reduces lipogenesis.
- Preclinical models show Resmetirom attenuates MDK/LRP1-mediated immunosuppression in MASLD/MASH-HCC.
- The article explores repurposing Resmetirom to suppress MASLD/MASH-HCC, considering epidemiology and treatment challenges.
- Discussion includes the link between thyroid hormone signaling, MASLD, and HCC pathogenesis.